

Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version 2.3 Revision Date: 30.09.2023 SDS Number: 5491617-00011 Date of last issue: 04.04.2023
Date of first issue: 10.03.2020

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Manufacturer or supplier's details

Company : MSD
Address : Briahnager - Off Pune Nagar Road
Wagholi - Pune - India 412 207
Telephone : +1-908-740-4000
Emergency telephone number : +1-908-423-6000
E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary medicine
Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

Classification

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

GHS Classification

Acute toxicity (Oral) : Category 4
Serious eye damage/eye irritation : Category 2A
Respiratory sensitisation : Category 1
Skin sensitisation : Category 1
Reproductive toxicity : Category 2
Short-term (acute) aquatic hazard : Category 1
Long-term (chronic) aquatic hazard : Category 1

Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version 2.3 Revision Date: 30.09.2023 SDS Number: 5491617-00011 Date of last issue: 04.04.2023
Date of first issue: 10.03.2020

GHS label elements

Hazard pictograms



Signal word

: Danger

Hazard statements

: H302 Harmful if swallowed.
H317 May cause an allergic skin reaction.
H319 Causes serious eye irritation.
H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.
H361d Suspected of damaging the unborn child.
H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements

: **Prevention:**
P203 Obtain, read and follow all safety instructions before use.
P261 Avoid breathing mist or vapours.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P272 Contaminated work clothing should not be allowed out of the workplace.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
P284 Wear respiratory protection.

Response:
P301 + P317 + P330 IF SWALLOWED: Get medical help. Rinse mouth.
P302 + P352 IF ON SKIN: Wash with plenty of water.
P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P318 IF exposed or concerned, get medical advice.
P333 + P317 If skin irritation or rash occurs: Get medical help.
P337 + P317 If eye irritation persists: Get medical help.
P342 + P316 If experiencing respiratory symptoms: Get emergency medical help immediately.
P362 + P364 Take off contaminated clothing and wash it before reuse.
P391 Collect spillage.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

SAFETY DATA SHEET

according to the Globally Harmonized System



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version 2.3 Revision Date: 30.09.2023 SDS Number: 5491617-00011 Date of last issue: 04.04.2023
Date of first issue: 10.03.2020

Additional Labelling

The following percentage of the mixture consists of ingredient(s) with unknown hazards to the aquatic environment: 33.36 %

Other hazards which do not result in classification

None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Dihydrostreptomycin sulphate	5490-27-7	$\geq 50 - < 70$
2-(4-Aminobenzoyloxy)ethyl-diethylammonium (6R)-6-(2-phenylacetamido)penicillanate monohydrate	6130-64-9	$\geq 30 - < 50$
Procaine hydrochloride	51-05-8	$\geq 1 - < 5$
Chlorphenamine hydrogen maleate	113-92-8	$\geq 1 - < 3$
Dexamethasone	50-02-2	$\geq 0.025 - < 0.1$

4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
If not breathing, give artificial respiration.
If breathing is difficult, give oxygen.
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
Never give anything by mouth to an unconscious person.
- Most important symptoms and effects, both acute and delayed : Harmful if swallowed.
May cause an allergic skin reaction.
Causes serious eye irritation.
May cause allergy or asthma symptoms or breathing difficulties if inhaled.
Suspected of damaging the unborn child.

SAFETY DATA SHEET

according to the Globally Harmonized System



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version 2.3 Revision Date: 30.09.2023 SDS Number: 5491617-00011 Date of last issue: 04.04.2023
Date of first issue: 10.03.2020

Protection of first-aiders : Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reactive airways dysfunction syndrome).
: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Nitrogen oxides (NO_x)
Sulphur oxides
Chlorine compounds
Metal oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.

Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version 2.3 Revision Date: 30.09.2023 SDS Number: 5491617-00011 Date of last issue: 04.04.2023
Date of first issue: 10.03.2020

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not get on skin or clothing.
Do not breathe mist or vapours.
Do not swallow.
Do not get in eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labelled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Dihydrostreptomycin sulphate	5490-27-7	TWA	OEB 2 (>= 100 < 1000 µg/m ³)	Internal
		TWA	0.4 mg/m ³	Customer derived OEL
Chlorphenamine hydrogen maleate	113-92-8	TWA	10 µg/m ³ (OEB 3)	Internal
Further information: Skin				
		Wipe limit	100 µg/100 cm ²	Internal
Dexamethasone	50-02-2	TWA	10 µg/m ³ (OEB 3)	Internal

Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.3	30.09.2023	5491617-00011	Date of first issue: 10.03.2020

	Further information: Skin		
	Wipe limit	100 µg/100 cm ²	Internal

Engineering measures : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Contaminated work clothing should not be allowed out of the workplace.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : suspension

Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version 2.3 Revision Date: 30.09.2023 SDS Number: 5491617-00011 Date of last issue: 04.04.2023
Date of first issue: 10.03.2020

Colour : white

Odour : No data available

Odour Threshold : No data available

pH : 5.0 - 6.0
No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : Not applicable

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : 1.17 - 1.21 g/cm³
No data available

Solubility(ies)
Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : No data available

Explosive properties : Not explosive

SAFETY DATA SHEET

according to the Globally Harmonized System



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version 2.3 Revision Date: 30.09.2023 SDS Number: 5491617-00011 Date of last issue: 04.04.2023
Date of first issue: 10.03.2020

Oxidizing properties : The substance or mixture is not classified as oxidizing.
Molecular weight : No data available
Particle size : Not applicable

10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : Can react with strong oxidizing agents.
Conditions to avoid : None known.
Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Harmful if swallowed.

Product:

Acute oral toxicity : Acute toxicity estimate: 709.59 mg/kg
Method: Calculation method

Components:

Dihydrostreptomycin sulphate:

Acute oral toxicity : LD50 (Rat): 430 mg/kg
Remarks: Based on data from similar materials

2-(4-Aminobenzoyloxy)ethyldiethylammonium (6R)-6-(2-phenylacetamido)penicillanate monohydrate:

Acute oral toxicity : LD50 (Mouse): > 2,000 mg/kg

Procaine hydrochloride:

Acute oral toxicity : LD50 (Rat): 200 mg/kg

Chlorphenamine hydrogen maleate:

Acute inhalation toxicity : LC50 (Rat): 0.61 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

SAFETY DATA SHEET

according to the Globally Harmonized System



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version 2.3 Revision Date: 30.09.2023 SDS Number: 5491617-00011 Date of last issue: 04.04.2023
Date of first issue: 10.03.2020

Acute toxicity (other routes of administration) : LD50 (Rat): 89 mg/kg

Dexamethasone:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
LD50 (Mouse): > 6,500 mg/kg

Acute toxicity (other routes of administration) : LD50 (Rat): 14 mg/kg
Application Route: Subcutaneous

Skin corrosion/irritation

Not classified based on available information.

Components:

2-(4-Aminobenzoyloxy)ethyl-diethylammonium (6R)-6-(2-phenylacetamido)penicillanate monohydrate:

Result : No skin irritation

Chlorphenamine hydrogen maleate:

Species : Rabbit
Result : No skin irritation

Dexamethasone:

Species : Rabbit
Result : Mild skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:

2-(4-Aminobenzoyloxy)ethyl-diethylammonium (6R)-6-(2-phenylacetamido)penicillanate monohydrate:

Result : No eye irritation

Chlorphenamine hydrogen maleate:

Species : Rabbit
Result : Severe irritation

Dexamethasone:

Species : Rabbit
Result : Mild eye irritation

Respiratory or skin sensitisation

Skin sensitisation

May cause an allergic skin reaction.

Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version 2.3 Revision Date: 30.09.2023 SDS Number: 5491617-00011 Date of last issue: 04.04.2023
Date of first issue: 10.03.2020

Respiratory sensitisation

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Components:

Dihydrostreptomycin sulphate:

Test Type : Human repeat insult patch test (HRIPT)
Exposure routes : Skin contact
Species : Humans
Result : positive
Remarks : Based on data from similar materials

Assessment : Probability or evidence of skin sensitisation in humans

2-(4-Aminobenzoyloxy)ethyl diethylammonium (6R)-6-(2-phenylacetamido)penicillanate monohydrate:

Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Method : OECD Test Guideline 406
Result : positive
Remarks : Based on data from similar materials

Assessment : Probability or evidence of skin sensitisation in humans

Assessment : Probability of respiratory sensitisation in humans based on animal testing

Chlorphenamine hydrogen maleate:

Exposure routes : Dermal
Remarks : No data available

Germ cell mutagenicity

Not classified based on available information.

Components:

Procaine hydrochloride:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Chlorphenamine hydrogen maleate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Mouse Lymphoma
Result: negative

Test Type: sister chromatid exchange assay

SAFETY DATA SHEET

according to the Globally Harmonized System



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version 2.3 Revision Date: 30.09.2023 SDS Number: 5491617-00011 Date of last issue: 04.04.2023
Date of first issue: 10.03.2020

Test system: Chinese hamster ovary cells
Result: positive

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Test system: rat hepatocytes
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Dexamethasone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: in vitro assay
Test system: mouse lymphoma cells
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Chlorphenamine hydrogen maleate:

Species : Rat
Application Route : Oral
Exposure time : 2 Years
NOAEL : 30 - 60 mg/kg body weight
Result : negative

Species : Mouse
Application Route : Oral
Exposure time : 2 Years
NOAEL : 20 - 50 mg/kg body weight
Result : negative

Reproductive toxicity

Suspected of damaging the unborn child.

Components:

Dihydrostreptomycin sulphate:

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

SAFETY DATA SHEET

according to the Globally Harmonized System



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version 2.3 Revision Date: 30.09.2023 SDS Number: 5491617-00011 Date of last issue: 04.04.2023
Date of first issue: 10.03.2020

Chlorphenamine hydrogen maleate:

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Oral
Fertility: LOAEL: 20 mg/kg body weight
Result: No effects on fertility, No effects on foetal development

Effects on foetal development : Test Type: Embryo-foetal development
Species: Mouse
Application Route: Oral
Developmental Toxicity: NOAEL: 20 mg/kg body weight
Result: Reduced embryonic survival, No malformations were observed.
Remarks: The significance of these findings for humans is not certain.

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: LOAEL: 15 mg/kg body weight
Result: No significant adverse effects were reported

Dexamethasone:

Effects on foetal development : Test Type: Development
Species: Mouse
Application Route: Subcutaneous
Developmental Toxicity: LOAEL: 6 mg/kg body weight
Result: Specific developmental abnormalities, Cleft palate

Species: Rabbit
Application Route: Intramuscular
Developmental Toxicity: NOAEL: 0.025 mg/kg body weight
Result: Specific developmental abnormalities

Species: Rabbit
Application Route: Intramuscular
Developmental Toxicity: LOAEL: \geq 0.062 mg/kg body weight
Result: Specific developmental abnormalities

Species: Rat
Application Route: Subcutaneous
Developmental Toxicity: LOAEL: \geq 0.02 mg/kg body weight
Result: Skeletal and visceral variations, Retardations

Reproductive toxicity - Assessment : May damage the unborn child.

STOT - single exposure

Not classified based on available information.

SAFETY DATA SHEET

according to the Globally Harmonized System



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version 2.3 Revision Date: 30.09.2023 SDS Number: 5491617-00011 Date of last issue: 04.04.2023
Date of first issue: 10.03.2020

Components:

Chlorphenamine hydrogen maleate:

Assessment : May cause drowsiness or dizziness.

STOT - repeated exposure

Not classified based on available information.

Components:

Chlorphenamine hydrogen maleate:

Target Organs : Cardio-vascular system
Assessment : May cause damage to organs through prolonged or repeated exposure.

Dexamethasone:

Exposure routes : Oral
Target Organs : Adrenal gland, Immune system, thymus gland
Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Chlorphenamine hydrogen maleate:

Species : Rat
NOAEL : 10 mg/kg
Application Route : Oral
Exposure time : 6 Weeks
Remarks : No significant adverse effects were reported

Species : Monkey
LOAEL : 15 mg/kg
Application Route : Oral
Exposure time : 105 Weeks
Target Organs : Heart

Dexamethasone:

Species : Rat
NOAEL : 0.0015 mg/kg
Application Route : Oral
Exposure time : 7 d
Target Organs : Liver
Remarks : Significant toxicity observed in testing

Species : Rat
LOAEL : 0.003 mg/kg
Application Route : Oral
Exposure time : 90 d
Target Organs : Blood, Adrenal gland, thymus gland

SAFETY DATA SHEET

according to the Globally Harmonized System



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version 2.3 Revision Date: 30.09.2023 SDS Number: 5491617-00011 Date of last issue: 04.04.2023
Date of first issue: 10.03.2020

Remarks : Significant toxicity observed in testing

Species : Rat
LOAEL : 0.125 mg/kg
Application Route : Oral
Exposure time : 6 Weeks
Target Organs : Adrenal gland
Remarks : Significant toxicity observed in testing

Species : Rat
LOAEL : 0.4 mg/kg
Application Route : Oral
Exposure time : 3 Months
Target Organs : Immune system
Remarks : Significant toxicity observed in testing

Species : Dog
LOAEL : 8 mg/kg
Application Route : Oral
Exposure time : 3 Months
Target Organs : Immune system
Remarks : Significant toxicity observed in testing

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Dihydrostreptomycin sulphate:

General Information : Target Organs: ear
Symptoms: hearing loss

Chlorphenamine hydrogen maleate:

Inhalation : Symptoms: central nervous system effects
Remarks: May cause respiratory tract irritation.
Skin contact : Remarks: May irritate skin.
Eye contact : Symptoms: Eye irritation
Remarks: May cause irreversible eye damage.
Ingestion : Symptoms: central nervous system effects
Remarks: Based on Human Evidence

Dexamethasone:

Ingestion : Target Organs: Immune system
Target Organs: Adrenal gland
Target Organs: Bone
Symptoms: muscle weakness

Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version 2.3 Revision Date: 30.09.2023 SDS Number: 5491617-00011 Date of last issue: 04.04.2023
Date of first issue: 10.03.2020

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Dihydrostreptomycin sulphate:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
Exposure time: 96 h
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Toxicity to algae/aquatic plants : EC50: > 0.01 - 0.1 mg/l
Remarks: Based on data from similar materials

M-Factor (Acute aquatic toxicity) : 10

M-Factor (Chronic aquatic toxicity) : 10

2-(4-Aminobenzoyloxy)ethyl-diethylammonium (6R)-6-(2-phenylacetamido)penicillanate monohydrate:

Ecotoxicology Assessment

Acute aquatic toxicity : Toxic effects cannot be excluded

Chronic aquatic toxicity : Toxic effects cannot be excluded

Procaine hydrochloride:

Ecotoxicology Assessment

Acute aquatic toxicity : Toxic effects cannot be excluded

Chronic aquatic toxicity : Toxic effects cannot be excluded

Dexamethasone:

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 56 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.2 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 9.2

SAFETY DATA SHEET

according to the Globally Harmonized System



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version 2.3 Revision Date: 30.09.2023 SDS Number: 5491617-00011 Date of last issue: 04.04.2023
Date of first issue: 10.03.2020

mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Toxicity to fish (Chronic toxicity) : NOEC: 0.033 mg/l
Exposure time: 32 d
Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210

M-Factor (Chronic aquatic toxicity) : 1

Persistence and degradability

Components:

Dexamethasone:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 50 %
Exposure time: 3.54 d
Method: OECD Test Guideline 314

Bioaccumulative potential

Components:

Dihydrostreptomycin sulphate:

Bioaccumulation : Species: Fish
Bioconcentration factor (BCF): 3.16

Partition coefficient: n-octanol/water : log Pow: -7.51

Procaine hydrochloride:

Partition coefficient: n-octanol/water : log Pow: 1.389

Dexamethasone:

Partition coefficient: n-octanol/water : log Pow: 1.83

Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version 2.3 Revision Date: 30.09.2023 SDS Number: 5491617-00011 Date of last issue: 04.04.2023
Date of first issue: 10.03.2020

Mobility in soil

No data available

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(Dihydrostreptomycin sulphate)

Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3082
Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.
(Dihydrostreptomycin sulphate)

Class : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 964
Packing instruction (passenger aircraft) : 964
Environmentally hazardous : yes

IMDG-Code

UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(Dihydrostreptomycin sulphate)

Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

SAFETY DATA SHEET

according to the Globally Harmonized System



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.3	30.09.2023	5491617-00011	Date of first issue: 10.03.2020

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

16. OTHER INFORMATION

Revision Date : 30.09.2023

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships;

SAFETY DATA SHEET

according to the Globally Harmonized System



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.3	30.09.2023	5491617-00011	Date of first issue: 10.03.2020

n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECL - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN